Psychedelic pharmaceutical company, MindMed, has begun trading on the OTCQB Venture Market as of April 17th, 2020. This is an upgrade to where they were previously trading in the U.S., on the OTC Pink Open Market, indicating the progress the company is making.

“We are very excited to start trading on the OTCQB as it will increase the Company’s visibility to U.S. investors and improves liquidity for our shareholders,” said MindMed CEO, JR Rahn.

This news comes one day after the company announced that it has initiated dosing in a human safety study of novel treatment for opioid addiction. Both of these achievements set MindMed apart from its competitors in the psychedelic industry.